The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Avidity Biosciences Inc (NASDAQ: RNA) closed the day trading at $41.71 up 1.76% from the previous closing price of $40.99. In other words, the price has increased by $1.76 from its previous closing price. On the day, 0.61 million shares were traded. RNA stock price reached its highest trading level at $42.39 during the session, while it also had its lowest trading level at $40.24.
Ratios:
For a better understanding of RNA, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 15.78 and its Current Ratio is at 15.78. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Barclays on August 28, 2024, initiated with a Overweight rating and assigned the stock a target price of $63.
On May 03, 2024, BofA Securities started tracking the stock assigning a Buy rating and target price of $40.
On March 14, 2024, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $60.Cantor Fitzgerald initiated its Overweight rating on March 14, 2024, with a $60 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 19 ’24 when LEVIN ARTHUR A sold 5,000 shares for $45.19 per share. The transaction valued at 225,946 led to the insider holds 14,830 shares of the business.
Boyce Sarah sold 28,000 shares of RNA for $1,213,822 on Aug 06 ’24. The President and CEO now owns 205,043 shares after completing the transaction at $43.35 per share. On Jul 19 ’24, another insider, LEVIN ARTHUR A, who serves as the Director of the company, sold 5,000 shares for $45.01 each. As a result, the insider received 225,069 and left with 14,830 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RNA now has a Market Capitalization of 4930914304 and an Enterprise Value of 3210095360. For the stock, the TTM Price-to-Sale (P/S) ratio is 460.86 while its Price-to-Book (P/B) ratio in mrq is 3.73. Its current Enterprise Value per Revenue stands at 302.868 whereas that against EBITDA is -11.356.
Stock Price History:
Over the past 52 weeks, RNA has reached a high of $48.80, while it has fallen to a 52-week low of $4.82. The 50-Day Moving Average of the stock is -3.74%, while the 200-Day Moving Average is calculated to be 67.86%.
Shares Statistics:
Over the past 3-months, RNA traded about 1.68M shares per day on average, while over the past 10 days, RNA traded about 1323730 shares per day. A total of 117.12M shares are outstanding, with a floating share count of 108.77M. Insiders hold about 7.13% of the company’s shares, while institutions hold 93.20% stake in the company. Shares short for RNA as of 1723680000 were 12918389 with a Short Ratio of 7.68, compared to 1721001600 on 12906004. Therefore, it implies a Short% of Shares Outstanding of 12918389 and a Short% of Float of 14.81.
